Fig. 2: Severe clinical outcomes among cases.

Plots illustrate cumulative 30-day risk of severe clinical outcomes among individuals first ascertained in outpatient settings, stratified by SGTF status for infecting variant or subvariant. Panels in the top row compare individuals with Delta (non-SGTF; red) or Omicron (SGTF; blue) variant infections testing positive in an outpatient setting between 15 December 2021 and 17 January 2022, for endpoints of any hospital admission (a); symptomatic hospital admission (b); ICU admission (c); mechanical ventilation (d); and death (e). Panels in the bottom row compare individuals with BA.2 (non-SGTF; yellow) and BA.1* (SGTF; blue, comprising BA.1/BA.1.1/BA.1.1.529 lineages) subvariant Omicron infections diagnosed in an outpatient setting between 3 February and 17 March 2022, for endpoints of any hospital admission (f); symptomatic hospital admission (g); ICU admission (h); and death (i). Mechanical ventilation among BA.2 and BA.1* Omicron subvariant individuals is not included due to sparse observations. Shaded areas denote 95% confidence intervals around median estimates (center lines). Analyses include 23,305 individuals with Delta variant infection and 222,688 individuals with Omicron variant infection over the period of 15 December 2021 to 17 January 2022 and 1,905 individuals with BA.2 Omicron subvariant infection and 12,756 individuals with BA.1* Omicron subvariant infection over the period of 3 February to 17 March 2022. Confidence intervals were obtained via bootstrap resampling.